luteinizing hormone-releasing hormone


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.
Related to luteinizing hormone-releasing hormone: luteinizing hormone-releasing hormone agonist

go·nad·o·tro·pin-re·leas·ing hor·mone (GnRH, GRH),

a decapeptide hormone from the hypothalamus that stimulates the anterior pituitary to release both follicle-stimulating hormone and luteinizing hormone. See: gonadotropin-releasing factor.

luteinizing hormone-releasing hormone

(hôr′mōn-rĭ-lē′sĭng)

luteinizing hormone-releasing hormone (LH-RH)

a neurohormone of the hypothalamus that stimulates and regulates the pituitary gland's release of luteinizing hormone.

lu·lib·er·in

(lū-lib'ĕr-in)
A decapeptide hormone from the hypothalamus that stimulates the anterior pituitary to release both follicle-stimulating hormone and luteinizing hormone.
Compare: bioregulator
Synonym(s): luteinizing hormone-releasing hormone.
[luteinizing hormone + L. libero, to free, + -in]
References in periodicals archive ?
Median testosterone levels grouped by treatment arm (Time @ -6 months = baseline testosterone level and first luteinizing hormone-releasing hormone agonist (LHRH-A) injection; time @ 0 months = end of LHRH-A treatment).
The company's initial product is a drug conjugate that combines the naturally-occurring anticancer substance curcumin with luteinizing hormone-releasing hormone (LHRH) that targets the hormone receptors present in large numbers on the surface of cancer cells.
Zoptarelin doxorubicin (AEZS-108) is the first intravenous drug in advanced clinical development that directs the chemotherapy agent specifically to Luteinizing Hormone-Releasing Hormone ("LHRH")-receptor expressing tumors, resulting in more targeted treatment with less damage to healthy tissue.
s Debio(R) PLGA proprietary technology, are one and three-month sustained-release formulations of triptorelin, an analog of luteinizing hormone-releasing hormone (LHRH or GnRH) with greater potency than naturally occurring LHRH.
AEZS-108 is the first intravenous drug in advanced clinical development that directs the chemotherapy agent specifically to Luteinizing Hormone-Releasing Hormone ("LHRH")-receptor expressing tumors, resulting in more targeted treatment with less damage to healthy tissue.
Utilizing Valera's Hydron Implant technology, Vantas(TM) has been designed for the continuous 12-month administration of histrelin, a synthetic nonapeptide agonist of luteinizing hormone-releasing hormone (LHRH).
Results showed the compound's high potential for the treatment of luteinizing hormone-releasing hormone (LHRH) receptor positive tumors.
Use of a compound such as luteinizing hormone-releasing hormone analogues (GnRH analogues), that disrupts sex steroid signaling (for modifying T cell population makeup or increasing the number of T cells) in a patient in the treatment or prevention of: an autoimmune disease; a hypersensitivity disease; cancer, including where the patient has undergone chemotherapy and/or radiation therapy and/or bone marrow transplantation; an infectious agent, including HIV; organ or bone marrow transplantation rejection; and vaccination against an infectious agent or a tumour cell.
These latest PSA results were observed in the 5-year extension study portion (CS21A) of a pivotal one-year, open-label, randomized phase III trial (CS21) that evaluated the efficacy of FIRMAGON, a gonadotropin-releasing hormone (GnRH) antagonist, and leuprolide, a luteinizing hormone-releasing hormone (LHRH) agonist, and formed the primary basis of the approval of FIRMAGON for advanced prostate cancer.

Full browser ?